Bezisterim (, ; developmental code names NE3107, HE3286) is a synthetic analogue of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood–brain barrier and does not activate any neurotransmitter receptors. It has been tested as a treatment for Alzheimer's disease, Parkinson's disease, traumatic brain injury,"U.S. Clinical Trial: Neurological Associates of West Los Angeles Listed a New Clinical Trial to Study Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury." Contify Life Science News, 1 Aug. 2023, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A759542006/HRCA?u=anon~bb46c85&sid=sitemap&xid=0c315c7e. Accessed 14 Dec. 2023. and post-acute COVID-19 syndrome (long COVID). The drug is under development for a variety of conditions and its highest developmental phase is phase 3 for Alzheimer's disease.
See also List of investigational cognition and memory disorder drugs List of investigational long COVID drugs List of investigational Parkinson's disease drugs
References